Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.195
+0.065 (5.75%)
Sep 18, 2025, 9:31 AM EDT - Market open
Allogene Therapeutics Revenue
In the year 2024, Allogene Therapeutics had annual revenue of $22.00K, down -76.84%.
Revenue (ttm)
$22.00K
Revenue Growth
-76.84%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
229
Market Cap
265.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22.00K | -73.00K | -76.84% |
| Dec 31, 2023 | 95.00K | -61.00K | -39.10% |
| Dec 31, 2022 | 156.00K | -113.93M | -99.86% |
| Dec 31, 2021 | 114.09M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ALLO News
- 22 days ago - Allogene Therapeutics Announces Participation in Upcoming Investor Conference - GlobeNewsWire
- 4 weeks ago - Allogene Therapeutics: Important Catalysts Guided For Early 2026 - Seeking Alpha
- 5 weeks ago - Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 6 weeks ago - Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update - GlobeNewsWire
- 6 weeks ago - Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma - GlobeNewsWire
- 3 months ago - Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO - GlobeNewsWire
- 3 months ago - Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment - Seeking Alpha